Holen Sie sich die Stockscreener-App
0.49
11.11%
0.049
Schlusskurs vom Vortag:
$0.441
Offen:
$0.4512
24-Stunden-Volumen:
3.11M
Relative Volume:
0.49
Marktkapitalisierung:
$36.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.1225
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
+14.11%
1M Leistung:
-12.72%
6M Leistung:
-77.00%
1J Leistung:
-73.37%
1-Tages-Spanne:
$0.44
$0.525
1-Wochen-Bereich:
$0.395
$0.525
52-Wochen-Spanne:
$0.3801
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.49 | 32.42M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Can Outlook Therapeutics Inc. stock maintain growth trajectoryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - TipRanks
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Outlook Therapeutics submits Type A meeting request to FDA following Complete Response Letter - marketscreener.com
Outlook Therapeutics Submit Type A Meeting Request To FDA Following CRL - Nasdaq
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter - TradingView
Outlook Therapeutics (OTLK) Faces FDA Request for Additional Evi - GuruFocus
Outlook Therapeutics seeks FDA meeting after response letter - Traders Union
FDA questions eye drug's evidence; Outlook Therapeutics seeks path forward - Stock Titan
Risk Check: Is Outlook Therapeutics Inc a top pick in the sectorEarnings Beat & Technical Confirmation Alerts - baoquankhu1.vn
Decliners Report: Can Outlook Therapeutics Inc reach all time highs this yearTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Recap: Should you buy the dip on Outlook Therapeutics IncAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Is Outlook Therapeutics Inc stock a buy or sellJuly 2025 Decliners & Intraday High Probability Setup Alerts - baoquankhu1.vn
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Outlook Therapeutics (OTLK) price target decreased by 43.42% to 5.48 - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ) - The Globe and Mail
Insider Trends: Is Outlook Therapeutics Inc stock a falling knife or bargain buy2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
US FDA declines to approve Outlook Therapeutics' eye disease drug - AOL.com
Will Outlook Therapeutics Inc. stock outperform international peersJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - ulpravda.ru
How Outlook Therapeutics Inc. (41ON) stock trades pre earnings2025 Price Momentum & Low Drawdown Trading Strategies - ulpravda.ru
How Outlook Therapeutics Inc. stock reacts to bond yieldsEarnings Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
Will Outlook Therapeutics Inc. (41O) stock beat revenue estimatesJuly 2025 Recap & Accurate Technical Buy Alerts - ulpravda.ru
Published on: 2026-01-09 04:38:07 - ulpravda.ru
What catalysts could drive Outlook Therapeutics Inc. stock higher2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Published on: 2026-01-09 02:26:13 - ulpravda.ru
Is Outlook Therapeutics Inc. (41O) stock attractive for dividend growthMarket Risk Analysis & Fast Gain Swing Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:30 - Улправда
Is Outlook Therapeutics Inc. stock oversold or undervaluedM&A Rumor & Accurate Entry/Exit Alerts - ulpravda.ru
Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development - VisionMonday.com
Is Outlook Therapeutics Inc. stock vulnerable to regulatory risksStock Rotation Strategies & High Return Portfolio Growth - ulpravda.ru
Outlook Therapeutics Inc. trading halted, news pending - MSN
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - sharewise.com
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Nigeria
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics price target lowered to 50c from $1 at HC Wainwright - MSN
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright By Investing.com - Investing.com South Africa
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):